Company Seeks Financial Partnerships For New RNA Spray That Combats Cannabis Hermaphroditism, Offers Affordable Male-Sterile Line Capability for Growers

LeafWorks, a trailblazing female-led plant genetics and testing company specializing in botanical identification for cannabis and hemp, has introduced a cutting-edge non-GMO classified RNA spray designed to control male sterility genes. This technology offers wide-ranging benefits, including mitigating the risk of cross-pollination and hermaphroditism and producing male-sterile plants for efficient hybrid seed production. The company has also submitted the technology prototype as a provisional patent application with the law offices of Fish and Richardson LLP to solidify patent protection on the use of male-sterile genes for commercial applications.

“Our customers are breeders and cultivators of all shapes and sizes, and the biggest solution they keep asking for is: ‘Can you help me with herming?’” said Dr. Eleanor Kuntz, LeafWorks CEO. “As a third-party testing and service provider, we are excited to be able to offer this solution.”

Hermaphroditism is one of the most difficult agricultural problems in cannabis and hemp. Hermaphroditic plants, which develop both male and female flowers, are common in commercial cultivation and can significantly harm crop success and product quality by causing unwanted pollination. Pollination significantly lowers cannabinoid and terpene production, shrinks flower size and number, and turns valuable flower into low-quality seeded product.

To solve this problem, LeafWorks developed a prototype spray that allows farmers to induce pollen sterility should male flowers form. This proprietary RNA-based spray technology will benefit the entire industry. Although difficult to capture, RNA forms naturally and is all around us. It is biodegradable and highly specific to its target—in this case, the male sterility genes in cannabis.

Male sterility, a condition in which plants' male reproductive organs do not produce viable pollen, is a crucial trait in crop breeding programs because it enables the development of hybrid seeds with superior yield, quality and uniformity compared to conventionally bred cultivars. LeafWorks’ technology can also be applied to breeders’ programs that want to make 100% male-sterile seed lines for hybrid-line production. With this technology, LeafWorks is leading the way to assist commercial cannabis and hemp breeders to produce hybrid seeds at scale.

Using sprays to alter the sex in cannabis plants is not a new technique. Breeders commonly use chemical sprays to create feminized seeds by activating the male flower genes. However, until now, no products have been able to successfully deactivate these male genes.

“Being able to control cross-pollination potential is a huge win for the industry,” said Dr. Kerin Law, LeafWorks Chief Scientific Officer. “We are adapting this knowledge into multiple applications so breeders at any scale can apply it however they see fit.”

Organizations interested in financial partnerships to develop the RNA spray for widespread commercial sale can reach out to info@leafworks.com. LeafWorks’ proprietary male sterility gene technology is also available to license to help cultivators develop male-sterile plant lines. More information can be found at https://leafworks.com/blogs/news/rna-spray-cannabis-hermaphroditism-solution.

About LeafWorks

LeafWorks Inc. is a plant genomics company conducting cutting-edge research and developing commercial DNA testing services for the cannabis and hemp markets. Co-founded by CEO Eleanor Kuntz, Ph.D., and CSO Kerin Law, Ph.D., LeafWorks operates with an unparalleled combination of scientific rigor and uncompromising ethics while specializing in plant identification and protecting, educating and empowering those stewarding the plants. The company also provides the necessary testing and services that help cultivators preserve their genetic IP, improve efficiency and ultimately evolve their grow. Learn more about LeafWorks Inc. at leafworks.com and connect on Facebook, Instagram, Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241121732933/en/